Tag Archives: BAY 3401016

Clinical Progress Continues as Evotec and Bayer Move Kidney Disease mAb Candidate Into Phase 2 Testing

Posted on 5, December 2025 by EuropaWire PR Editors

(IN BRIEF) Evotec SE announced that Bayer has initiated a Phase 2 clinical study for BAY 3401016, a Semaphorin-3A-targeting monoclonal antibody being developed as a potential therapeutic option for patients with Alport syndrome. As part of the companies’ kidney disease … Read the full press release →

Posted in Business, Germany, Healthcare, Investment, News, Pharma & Biotech, Science, Technology

Tagged Alport syndrome, ASSESS study, BAY 3401016, Bayer, clinical development, COL4A3, COL4A4, COL4A5, end stage renal disease, Evotec, Evotec Announces Phase 2 Advancement of BAY 3401016 for Alport Syndrome in Collaboration with Bayer, milestone payment, monoclonal antibody, phase 2 trial, podocytes, rare kidney disease, Sema3A, Semaphorin-3A